[Platelet activating factor and tumor necrosis factor-alpha in bronchoalveolar lavage fluid of patients with ARDS]. 1993

K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
Second Department of Medicine, Nagoya University School of Medicine, Japan.

Platelet activating factor (PAF) and tumor necrosis factor alpha (TNF-alpha) were examined in the bronchoalveolar lavage fluid (BALF) of 21 ARDS patients to clarify the role of these factors in ARDS. Neutrophil percentages and albumin concentrations in the BALF of the ARDS group were markedly elevated compared with those in the control group (p < 0.01), showing a significant correlation (r = 0.596, p < 0.01). PAF was detected in 14 of 19 ARDS patients (237.5 +/- 86.0 pg/ml) and TNF-alpha was detected in 7 of 16 ARDS patients (24.9 +/- 13.6 pg/ml), whereas these factors were not detected in control subjects. Neither PAF nor TNF-alpha showed a significant correlation with neutrophil percentage, neutrophil number or albumin concentration. They do not seem to be contributing factors to the prognosis of ARDS patients. However the existence of PAF and TNF-alpha in the BALF of some ARDS patients suggests that they might play a role in the pathogenesis of ARDS.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D012128 Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. ARDS, Human,Acute Respiratory Distress Syndrome,Adult Respiratory Distress Syndrome,Pediatric Respiratory Distress Syndrome,Respiratory Distress Syndrome, Acute,Respiratory Distress Syndrome, Adult,Respiratory Distress Syndrome, Pediatric,Shock Lung,Distress Syndrome, Respiratory,Distress Syndromes, Respiratory,Human ARDS,Lung, Shock,Respiratory Distress Syndromes,Syndrome, Respiratory Distress
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
April 1990, The European respiratory journal,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
August 1992, The American review of respiratory disease,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
March 1994, Nihon Kyobu Shikkan Gakkai zasshi,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
July 1994, International archives of allergy and immunology,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
August 2018, Veterinary immunology and immunopathology,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
July 1997, American journal of respiratory and critical care medicine,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
January 1997, Journal of perinatology : official journal of the California Perinatal Association,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
August 1991, The American review of respiratory disease,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
June 1991, Chest,
K Matsumoto, and F Taki, and Y Kondo, and H Taniguchi, and K Takagi, and M Matsuzaki, and H Kayahara
January 1999, The European respiratory journal,
Copied contents to your clipboard!